Production of cerium-141 using ceria and nanoceria powder: a potential radioisotope for simultaneous therapeutic and diagnostic applications

Soltani, Fatemeh; Bahrami-Samani, Ali; Sadeghi, Mahdi; Arani, Simindokht Shirvani; Yavari, Kamal

doi:10.1007/s10967-014-3335-3

Cited by 13 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hadronic bombardment is performed by irradiating the pre‐fabricated MNPs via accelerated particles, such as neutrons (Cipreste et al, 2016; Lipka et al, 2010; Munaweera et al, 2015; Soltani et al, 2015), protons (Hildebrand & Franke, 2012; Hildebrand et al, 2015), or deuterons (Simonelli et al, 2011), to induce nuclear reactions converting the stable isotopes in MNP lattice to radioisotopes, thus resulting in radiolabeled MNPs (Koziorowski et al, 2017). As the induced nuclear reactions occur at the level of nuclei, whose yields are determined by the cross sectional area of the corresponding nuclei (Jelley, 1990), the radiolabeling of the MNPs by this approach can be technically controlled by the beam‐line energy, current, and bombardment time.…”

Section: Radiolabeling Of Mnpsmentioning

confidence: 99%

Radiolabeling strategies and pharmacokinetic studies for metal based nanotheranostics

Bahadori

Mulgaonkar

Hart

et al. 2020

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Radiolabeled metal‐based nanoparticles (MNPs) have drawn considerable attention in the fields of nuclear medicine and molecular imaging, drug delivery, and radiation therapy, given the fact that they can be potentially used as diagnostic imaging and/or therapeutic agents, or even as theranostic combinations. Here, we present a systematic review on recent advances in the design and synthesis of MNPs with major focuses on their radiolabeling strategies and the determinants of their in vivo pharmacokinetics, and together how their intended applications would be impacted. For clarification, we categorize all reported radiolabeling strategies for MNPs into indirect and direct approaches. While indirect labeling simply refers to the use of bifunctional chelators or prosthetic groups conjugated to MNPs for post‐synthesis labeling with radionuclides, we found that many practical direct labeling methodologies have been developed to incorporate radionuclides into the MNP core without using extra reagents, including chemisorption, radiochemical doping, hadronic bombardment, encapsulation, and isotope or cation exchange. From the perspective of practical use, a few relevant examples are presented and discussed in terms of their pros and cons. We further reviewed the determinants of in vivo pharmacokinetic parameters of MNPs, including factors influencing their in vivo absorption, distribution, metabolism, and elimination, and discussed the challenges and opportunities in the development of radiolabeled MNPs for in vivo biomedical applications. Taken together, we believe the cumulative advancement summarized in this review would provide a general guidance in the field for design and synthesis of radiolabeled MNPs towards practical realization of their much desired theranostic capabilities. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Diagnostic Tools > Diagnostic Nanodevices Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

show abstract

Section: Radiolabeling Of Mnpsmentioning

confidence: 99%

Radiolabeling strategies and pharmacokinetic studies for metal based nanotheranostics

Bahadori

Mulgaonkar

Hart

et al. 2020

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…14 The production of 141 Ce-ceria and nanoceria powders as potential imaging and therapeutic agents has been examined. 15 144 Ce/ 144 Pr generator 144 Ce is a fission product, undergoing radioactive decay with a half-life of 284.1 d via b -emission to 144 Pr. 144 Pr has a half-life of 17.3 min and decays via b -emission to 144 Nd.…”

Section: Ce/ Lamentioning

confidence: 99%

“…Of central importance is the β + emission energy (not to be confused with the 511 keV annihilation energy) which determines the range of the emitted positrons (mean free paths) in condensed matter, and hence set a limit to the resolution of PET scans. To illustrate this we can compare the well documented examples of 18 F and 15 O, which possess maximum emission energies of 675 and 1720 keV respectively, with the corresponding FWTM (full width at tenth of maximum) scatter values of 1.03 mm and 4.14 mm. 2 The lower 'scatter' of 18 F results in considerably better spatial resolution in PET imaging.…”

Section: Introductionmentioning

confidence: 99%

Chelating agents for radiolanthanides: Applications to imaging and therapy

Amoroso

Fallis

Pope

2017

Coordination Chemistry Reviews

View full text Add to dashboard Cite

“…47 Sc has a shorter half-life than 177 Lu owing to its rapid pharmacokinetics. Therefore, it may be useful for the treatment and diagnosis of tumors [ 18 ]. However, the therapeutic efficacy of 47 Sc in preclinical and clinical studies is still largely unknown compared with that of 177 Lu.…”

Section: Introductionmentioning

confidence: 99%

RUNX3 regulates the susceptibility against EGFR-targeted non-small cell lung cancer therapy using 47Sc-conjugated cetuximab

et al. 2023

View full text Add to dashboard Cite

Background Radioimmunotherapy with cetuximab and conjugates with various radioisotopes is a feasible treatment option for different tumor models. Scandium-47 (47Sc), one of several β−-particle-emitting radioisotopes, displays favorable physical and chemical properties for conjugation to monoclonal antibodies. However, the therapeutic efficacy of 47Sc in preclinical and clinical studies is largely unknown. Given that intrinsic alterations in tumors greatly contribute to resistance to anti-epidermal growth factor receptor (EGFR)-targeted therapy, research on overcoming resistance to radioimmunotherapy using cetuximab is required. Methods 47Sc was produced by irradiation of a CaCO3 target at the HANARO research reactor in KAERI (Korea Atomic Energy Research Institute) and prepared by chromatographic separation of the irradiated target. Cetuximab was conjugated with 47Sc using the bifunctional chelating agent DTPA. Radiochemical purity was determined using instant thin-layer chromatography. The immunoreactivity of 47Sc-DTPA-cetuximab was evaluated using the Lindmo method and an in vitro cell-binding assay. The inhibitory effects of cetuximab and 47Sc-DTPA-cetuximab were confirmed using cell growth inhibition and BrdU cell proliferation assays. Differences in protein expression levels between cetuximab- and 47Sc-DTPA-cetuximab-treated cells were confirmed using western blotting. Complex formation between RUNX3 and DNA repair components was confirmed using immunoprecipitation and western blotting. Results Cetuximab induces cell cycle arrest and cell death in EGFR-overexpressing NSCLC cells. Radiolabeling of cetuximab with 47Sc led to increased therapeutic efficacy relative to cetuximab alone. Application of 47Sc-DTPA-cetuximab induced DNA damage responses, and activation of RUNX3 significantly enhanced the therapeutic efficacy of 47Sc-DTPA-cetuximab. RUNX3 mediated susceptibility to EGFR-targeted NSCLC therapy using 47Sc-DTPA-cetuximab via interaction with components of the DNA damage and repair machinery. Conclusions 47Sc-DTPA-cetuximab promoted cell death in EGFR-overexpressing NSCLC cells by targeting EGFR and inducing DNA damage as a result of β irradiation emitted from the conjugated 47Sc. Activation of RUNX3 played a key role in DNA damage and repair processes in response to the ionizing radiation and inhibited cell growth, thus leading to more effective tumor suppression. RUNX3 can potentially moderate susceptibility to 47Sc-conjugated cetuximab by modulating DNA damage and repair process mechanisms.

show abstract

Production of cerium-141 using ceria and nanoceria powder: a potential radioisotope for simultaneous therapeutic and diagnostic applications

Cited by 13 publications

References 25 publications

Radiolabeling strategies and pharmacokinetic studies for metal based nanotheranostics

Radiolabeling strategies and pharmacokinetic studies for metal based nanotheranostics

Chelating agents for radiolanthanides: Applications to imaging and therapy

RUNX3 regulates the susceptibility against EGFR-targeted non-small cell lung cancer therapy using 47Sc-conjugated cetuximab

Contact Info

Product

Resources

About